|
ИСТИНА |
Войти в систему Регистрация |
Интеллектуальная Система Тематического Исследования НАукометрических данных |
||
448P Efficacy of combinations of BRAF inhibitors and anti-EGFR antibodies in metastatic colorectal carcinoma (mCRC) patients with mBRAF in the real clinical practiceстатья
Статья опубликована в высокорейтинговом журнале
Статья опубликована в журнале из списка Web of Science и/или ScopusДата последнего поиска статьи во внешних источниках: 20 июня 2024 г.
- Авторы: Fedyanin M., Elsnukaeva H., Demidova I., Stroyakovskiy D., Shelygin Y., Tsukanov A., Panina M., Moiseenko F., Karpenko E., Bolotina L., Kudryavtseva A., Filipenko M., Oskorbin I., Vladimirova L.Y., Timoshkina N.N., Kit O.I., Stroganova A., Dranko S., Tryakin A., Tjulandin S.
- Журнал: Annals of Oncology
- Том: 32
- Год издания: 2021
- Издательство: Oxford University Press
- Местоположение издательства: United Kingdom
- Первая страница: S557
- Последняя страница: S558
- DOI: 10.1016/j.annonc.2021.08.969
- Аннотация: Background Combination of BRAF inhibitors and anti-EGFR antibodies is a standard of 2nd and subsequent line of treatment in pts with mBRAF mCRC. We performed analysis of prospective multicentric database of pts with mBRAF metastatic CRC to evaluate the efficacy of such approach in the real clinical practice. Methods We analyzed a database of pts with mCRC in 7 cancer clinics in Russia and chose pts with 2nd and subsequent lines. The primary endpoints were progression free survival (PFS) and overall survival (OS), which were calculated from the time of starting systemic treatment. Analysis was performed with the SPSS v.20 software package. Results The study included 73 pts with mBRAF. All pts had V600 mutations; female - 70%, average age - 69 years (20-79), MSI-H -10%; the right-sided primary tumor – 53%; the primary tumor was removed in 81%, adjuvant chemotherapy was administered in 32%; lung metastases – in 29%, liver - 53%, peritoneal metastases – in 44%; metastasectomy was performed in 22% pts. The first line was FOLFOXIRI in 19%. BRAF inhibitors and anti-EGFR were administered in 30 pts (42%): in the 2nd line – 18 (60%), 3rd line – 7 (23%), 4-5th lines – 5 (17%). Chemotherapy was administered in the 2nd line in 43 (58%) pts: with bevacizumab or aflibercept in 52%. In pts with BRAF inhibitors and anti-EGFR treatment ORR was 27%, with 7% CR, disease control rate was 60%, median PFS was 4 months (95% CI 1,2-6,8), and OS – 11 months (95% CI 8,5-13,4). There were no statistical differences between chemotherapy group and combinations of BRAF inhibitors and anti-EGFR treatment in 2nd line neither in PFS (HR 1,3, 95% CI 0,7-2,5, p=0,4) or OS (R 1,4, 95% CI 0,52-4,0, p=0,5) Conclusions treatment with BRAF inhibitors and anti-EGFR antibodies shows the same efficacy as in BEACON study in pts with mutant BRAF mCRC in real clinical practice. However, there were no survival benefit in comparison with another systemic treatment in the 2nd line, this suggests we need a prospective randomized study to compare BRAF inhibitors combinations and chemotherapy with anti-VEGF agents in the 2nd line of treatment.
- Добавил в систему: Владимирова Любовь Юрьевна